Group 1 - The company Tianyu Co., Ltd. (300702) announced on the evening of August 20 that it has received the Certificate of Suitability for European Pharmacopoeia (CEP) for the raw material drug Dabigatran Etexilate Mesylate issued by the European Directorate for the Quality of Medicines (EDQM) [1]

格隆汇8月20日丨天宇股份(300702.SZ)公布，公司收到欧洲药品质量管理局(简称"EDQM")签发的关于 甲磺酸达比加群酯原料药的欧洲药典适用性认证证书。 甲磺酸达比加群酯主要用于预防存在一个或多个危险因素的成人非瓣膜性房颤患者的卒中和体循环栓 塞；治疗急性深静脉血栓形成和/或肺栓塞以及预防相关死亡；预防复发性深静脉血栓形成和/或肺栓塞 以及相关死亡。 ...